Blueprint Medicines Corp【BPMC】

時価総額

$83.6億

PER

アレルギー/炎症、腫瘍/血液領域のグローバル統合型バイオ医薬品の有力企業。AYVAKITを含む承認薬2製品や創薬プラットフォームを展開。2011年から創薬基盤を構築、2024年にRigel関連資産を取得。米国・欧州中心に展開。

	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-	-	-148	-237	-348	314	-644	-558	-507	-67
Depreciation and amortization	1	2	2	4	5	7	6	12	12	16
Non-cash lease expense	-	-	-	-	5	6	6	8	9	10
Stock-based compensation	5	6	13	31	55	76	92	99	93	109
Noncash Interest Expense	-	-	-	-	-	-	-	16	14	1
Non-cash customer consideration	-	-	-	-	-	-	-	28	-	-
Non-cash debt extinguishment gain	-	-	-	-	-	-	-	-	-	174
Net (accretion of discount) amortization of premium on investments	-	-	-	-	-	-	-	-	17	22
Other	-	-	-	-0	-	0	3	3	1	-1
Accounts receivable	-	-	-	-	1	6	18	-2	21	33
Unbilled accounts receivable	-	-	-	-	23	-5	-6	4	-13	-0
Inventory	-	-	-	-	-	7	13	9	4	4
Prepaid expenses and other current assets	1	-1	7	-6	3	13	-5	17	-3	3
Other assets	1	0	0	4	-0	-1	2	16	5	11
Accounts payable	1	0	2	-0	1	-1	4	-6	2	2
Accrued expenses	2	6	15	25	37	16	6	9	1	8
Other long-term liabilities	-	-	-	-	-	-	-	-	-7	-12
Deferred revenue	-	-	-	5	-0	-5	-5	-5	-13	-0
Operating lease liabilities	-	-	-	-	-	-	-8	-8	-11	-12
Net cash used in operating activities	-	-	-120	-175	-278	387	-299	-502	-437	-193
Purchases of property and equipment	5	2	16	13	14	3	3	9	16	5
Purchases of investments	-	264	361	801	738	969	655	490	766	966
Maturities of investments	-	48	304	653	736	538	691	349	1,056	924
Other	-	-	-	-	-	-	-	0	-	-
Net cash provided by (used in) investing activities	-	-	-76	-161	-16	-434	-226	-150	274	-48
Proceeds from at-the-market offerings, net of issuance costs	-	-	-	-	-	503	-	-	-	49
Net proceeds from stock option exercises and employee stock purchase plan	-	-	-	-	-	35	51	8	21	78
Net proceeds from term loan facility	-	-	-	-	-	-	-	138	98	147
Proceeds from (Repayments of) Other Long-Term Debt	-	-	-	-	-	-	-	416	-	-
Principal payments for financing arrangements	-	-	-	-	-	-	-	-	-	1
Net cash provided by financing activities	-	-	544	4	341	618	51	562	119	273
Net increase (decrease) in cash, cash equivalents, and restricted cash	-	-	-	-	-	-	-	-	-44	33
Effect of exchange rate changes on cash, cash equivalents and restricted cash	-	-	-	-	-	-	-	-0	0	-1
Cash paid for interest	0	0	0	0	0	-	-	10	38	80
Capital Expenditures Incurred but Not yet Paid	1	-	4	1	1	0	0	0	1	0
Income Taxes Paid, Net	-	-	-	-	0	1	1	7	-0	1